logo

Immunogen Inc (IMGN)



Trade IMGN now with
  Date
  Headline
8/31/2022 6:36:32 AM ImmunoGen Updates On CADENZA Study Of Pivekimab Sunirine In Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
7/29/2022 6:37:11 AM ImmunoGen Q2 Total Revenues $14.2 Mln Vs. $16.9 Mln Prior Year
6/13/2022 6:36:35 AM ImmunoGen Collaborates With Oxford BioTherapeutics To Develop Novel Antibody-Drug Conjugates
5/23/2022 6:34:26 AM ImmunoGen: FDA Accepts BLA For Mirvetuximab Soravtansine In Ovarian Cancer With Priority Review
5/6/2022 6:38:15 AM ImmunoGen Q1 Net Loss $24.1 Mln Or $0.10/Shr Vs Loss Of $34.1 Mln Or $0.17/Shr Last Year
3/29/2022 6:50:26 AM ImmunoGen Submits BLA To FDA For Mirvetuximab Soravtansine In Ovarian Cancer
3/10/2022 6:35:42 AM ImmunoGen To Present Full Results From SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer
2/15/2022 6:41:53 AM ImmunoGen Announces License Agreement Of Camptothecin ADC Platform To Lilly For Up To $1.7 Bln
1/31/2022 6:32:42 AM ImmunoGen Appoints Mimi Huizinga As SVP And Head Of Medical Affairs
12/12/2021 9:37:51 AM ImmunoGen Presents Initial Findings From Phase 1b/2 Study Of IMGN632 With Vidaza And Venclexta In R/R AML At ASH
12/2/2021 12:16:14 AM ImmunoGen Announces Pricing Of 11.64 Mln Shares At $6.60/Shr